T. Koyanagi

发表

Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B

H. Nomura, J. Hayashi, N. Furusyo, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

H. Nomura, J. Hayashi, N. Furusyo, 2022, Alimentary pharmacology & therapeutics.

Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment

H. Nomura, J. Hayashi, N. Furusyo, 2018, Alimentary pharmacology & therapeutics.

Spontaneous regression of multiple lung metastases of hepatocellular carcinoma: report of two cases

A. Masumoto, M. Yada, K. Motomura, 2012 .

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.

H. Nomura, J. Hayashi, N. Furusyo, 2016, Antiviral research.

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

H. Nomura, J. Hayashi, K. Kotoh, 2015, Journal of viral hepatitis.

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b

H. Nomura, J. Hayashi, N. Furusyo, 2017, Journal of Gastroenterology.

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

H. Nomura, J. Hayashi, K. Kotoh, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non‐cirrhotic patients with chronic hepatitis C virus genotype 1b infection

H. Nomura, J. Hayashi, K. Kotoh, 2015, Journal of gastroenterology and hepatology.

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.

H. Nomura, J. Hayashi, Hwai I. Yang, 2019, Clinical Infectious Diseases.

Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C

H. Nomura, J. Hayashi, K. Kotoh, 2015, Journal of gastroenterology and hepatology.

Liver abscess due to Fusobacterium caused by dental bacterial infection: report of two cases

A. Masumoto, M. Yada, K. Motomura, 2013 .

A case of acute hepatitis due to Lyme disease

A. Masumoto, Y. Sano, M. Yada, 2010 .

Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real‐world cohort study focusing on chronic kidney disease

H. Nomura, J. Hayashi, N. Furusyo, 2018, Antiviral research.

Long‐term hepatic function of patients with compensated cirrhosis following successful direct‐acting antiviral treatment for hepatitis C virus infection

H. Nomura, J. Hayashi, N. Furusyo, 2021, Journal of gastroenterology and hepatology.

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study

M. Nakamuta, M. Kohjima, Tsuyoshi Yoshimoto, 2022, Medicine.

Pruritus in Chronic Liver Disease: A Questionnaire Survey on 216 Patients.

J. Hayashi, K. Kotoh, N. Furusyo, 2019, Acta dermato-venereologica.

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma

M. Nakamuta, M. Kohjima, Tsuyoshi Yoshimoto, 2022, Internal medicine.

A case of cirrhosis due to pravastatin-induced autoimmune hepatitis

A. Masumoto, M. Yada, K. Motomura, 2010 .

Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.

H. Nomura, J. Hayashi, K. Kotoh, 2015, World journal of hepatology.

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study

H. Nomura, J. Hayashi, N. Furusyo, 2021, Hepatology International.

Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study

H. Nomura, J. Hayashi, N. Furusyo, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma--results of 152 resected cases.

K. Shirabe, T. Nagaie, T. Gion, 2007, Hepato-gastroenterology.

Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan

H. Nomura, J. Hayashi, N. Furusyo, 2019, BMJ Open.

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals

H. Nomura, J. Hayashi, N. Furusyo, 2021, Journal of gastroenterology and hepatology.

Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.

A. Masumoto, M. Yada, K. Motomura, 2010, World journal of gastroenterology.

Pruritus in chronic liver disease: a questionnaire survey in 71 patients

J. Hayashi, K. Kotoh, N. Furusyo, 2016 .

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals

H. Nomura, J. Hayashi, N. Furusyo, 2020, The Journal of infectious diseases.

Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis

H. Nomura, J. Hayashi, N. Furusyo, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Two cases of hepatocellular carcinoma with erythrocytosis

K. Shirabe, N. Harimoto, T. Nagaie, 2009 .

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C

H. Nomura, J. Hayashi, N. Furusyo, 2020, Cancers.

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort

H. Nomura, J. Hayashi, Hwai I. Yang, 2020, Hepatology International.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

A. Masumoto, M. Yada, K. Motomura, 2014, World journal of gastroenterology.